STOCKHOLM, July 9, 2020 /PRNewswire/ -- IRLAB
announced today that a scientific paper reporting the distinctive
pharmacological profile of IRL752, in development for the treatment
of impaired balance and falls in Parkinson's disease, is accepted
and published online in the Journal of Pharmacology and
Experimental Therapeutics, JPET.
"This paper was the result of a successful cross-disciplinary
collaboration between scientists at IRLAB and an academic research
group in the UK. To share our research within an international
network and explore the potential of our drug candidate in a
renowned independent lab, specialized in studies of cognitive
processes, is significant for us. I would also like to emphasize
the importance of these scientific findings for the continued
clinical development and, ultimately, the change we hope IRL752
will bring to affected patients and their caregivers," says
Stephan Hjorth, Ph.D., Prof., senior
scientific advisor at IRLAB.
JPET, The Journal of Pharmacology and Experimental
Therapeutics, is a highly ranked international research journal
in the field of pharmacology. The journal is published by The
American Society for Pharmacology and Experimental Therapeutics
(ASPET).
IRL752 is a drug candidate in clinical Phase II and is in
development by IRLAB for the treatment of impaired balance
(postural dysfunction) and falls in Parkinson's disease (PD-Falls).
The paper reports the pharmacological profile of IRL752,
characterized by facilitatory impact on cortical noradrenaline,
dopamine and acetylcholine neurotransmission, accompanied by
improved cognitive functions. This pharmacological profile is in
line with the potential clinical usefulness of IRL752 in conditions
where cortical neurotransmission may be dysregulated, such as the
axial motor and cognitive deficits associated with impaired balance
and falls in Parkinson's Disease. The effect profile of IRL752 was
characterized through in vivo studies, assessing effects on
behavior, neurotransmission and gene expression, as well as in
vitro assays investigating receptor interactions.
The paper was published online as part of JPET Fast
Forward, which contains papers in manuscript form that have
been accepted and published in JPET but have not been
copyedited and have not been assigned to an issue of the journal.
Copyediting, including graphics, may lead to some differences
between the Fast Forward version and the final version.
Paper: Hjorth, S. et al.
(3S)-3-(2,3-difluorophenyl)-3-methoxypyrrolidine (IRL752) - a novel
cortical-preferring catecholamine transmission- and
cognition-promoting agent. Journal of Pharmacology and
Experimental Therapeutics, DOI: 10.1124/jpet.120.000037.
For more information
Nicholas Waters, CEO
Phone:
+46-730-75-77-01
E-mail: nicholas.waters@irlab.se
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/irlab-therapeutics-ab/r/irlab-s-clinical-drug-candidate-irl752-published-in-jpet,c3151154
The following files are available for download:
https://mb.cision.com/Main/15440/3151154/1276777.pdf
|
IRLAB Press release
IRL752 JPET - ENG
|